source
- FDA grants accelerated approval to J&J's Rybrevant for recurrent head and neck cancerThe U.S. Food and Drug Administration has issued an accelerated approval for Johnson & Johnson's antibody-drug conjugate Rybrevant targeting head and neck cancers that have returned after prior che…
- Medicare to slash 340B drug payments and expand site-neutral rules in 2027Medicare finalized a rule that will cut payments for drugs covered by the 340B discount program and broaden site-neutral payment policies beginning in 2027. The rule is expected to reduce Medicare…